Creso Pharma (ASX:CPH) share price climbs on increasing revenue update

The company's shares have gained close to 30% in a month…

| More on:
high, climbing, record high

Image Source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Creso Pharma Ltd (ASX: CPH) share price is on the move on Thursday. This comes as the cannabis and psychedelics company released a positive trading update for Q4 FY21.

During early afternoon trade, Creso shares are swapping hands for 14.8 cents apiece, up 1.72%.

What did Creso announce?

According to the release, Creso advised that it has recorded strong revenues from its Swiss operations in the current fourth-quarter.

To date, the division's revenue has soared past $0.8 million, which is a 126% increase compared to the last quarter. Underpinning the performance, Creso experienced an uptick in human health CBD and medical cannabis product sales from Swiss-based company, Cannahealth.

Creso Pharma entered into a strategic collaboration agreement with Cannahealth, for the supply of hemp and cannabis plant material. The latter will also provide marketing and sales of Creso's products in Switzerland.

Both parties are discussing the potential of extending Creso's reach into other countries in Europe.

The initial term of the agreement is valid for 1-year and automatically renews unless terminated by either company.

In addition, Creso has expanded its sales pipeline over recent months and anticipates additional purchase orders through its Swiss operations. Furthermore, wholly-owned Canadian subsidiary, Mernova Medical Inc. is also expected to provide a boost in sales in the near term.

Creso's cannaDOL launch campaign is now being delivered to more than 2,500 retailers across Switzerland. The products are being distributed to several key pharmacies which could lead to rapid growth for the company. Other distribution sites include drugstores, fitness centres, and e-commerce channels.

Creso non-executive chair, Adam Blumenthal commented:

We anticipate that revenue will continue to increase over the remainder of Q4 2021, when additional purchase orders across Switzerland and Canada materialise. The company has a number of business development initiatives underway and remains committed to significantly growing its sales pipeline through international expansion efforts and partnership agreements.

About the Creso share price

Over the past 12 months, the Creso share price has rocketed 361%, reflecting positive investor sentiment. The company's shares reached a 52-week high of 47 cents in early December 2020. Lawmakers in the United States passed a bill to decriminalise cannabis on a national level, which shot up Creso shares.

Based on today's price, Creso presides a market capitalisation of roughly $177.96 million, with approximately 1.2 billion shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Cannabis Shares

Man in a cannabis greenhouse looks unhappy and puts his thumb down.
Cannabis Shares

Why are these 2 ASX cannabis stocks sputtering today?

Up 174% in 2023, this ASX cannabis share is giving back some more of its gains today.

Read more »

A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
Cannabis Shares

Guess which ASX cannabis share is crashing 36% following an FDA blow

Rookie mistake: This cannabis share just missed out on FDA approval for a simple reason.

Read more »

A Cronos Australia farmer and ASX cannabis shares investor stands in a field of cannabis plants and smiles at the camera
Cannabis Shares

Could ASX cannabis shares be set for a resurgence?

The world's legal and medical fraternities are taking small steps forward in the medicinal cannabis movement.

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Cannabis Shares

This ASX cannabis stock is up 160% since June, and it has an FDA ruling coming up!

Investors are very excited about this cannabis stock.

Read more »

two men in formal business clothing closely inspect a bud from a cannabis crop.
Cannabis Shares

Why ASX cannabis shares just jumped back into the spotlight

ASX cannabis shares operate in a nation where medical marijuana is legal but recreational use remains broadly forbidden.

Read more »

A hip young man with a beard and manbun sits thoughtfully at his laptop computer in a darkened room, staring at the screen with his chin resting on his hand in thought.
Cannabis Shares

Should I buy Incannex shares while they're at multi-year lows, or steer clear?

Is the cannabis-based pharma company a bargain buy right now?

Read more »

Man in the green house growing medical cannabis
Cannabis Shares

A $3k investment in ASX cannabis stock Incannex 5 years ago is now worth $15,000. Here's why

This medicinal cannabis company has been a rare winner in its field.

Read more »

a man wearing old fashioned aviator cap and goggles emerges from the top of a cannon pointed towards the sky. He is holding a phone and taking a selfie.
Cannabis Shares

Which ASX cannabis share is surging 27% on record quarterly results?

Althea CEO Josh Fegan has declared "a landmark turning point" for the company.

Read more »